Results 121 to 130 of about 25,328 (173)

Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315). [PDF]

Cancers (Basel)
Stuschke M, Thomas M, Gröschel A, Sebastian M, Reck M, Hoffknecht P, Grah C, Spring L, Jänicke M, Lennartz C, Ludwig P, Groth A, Sadjadian P, Christopoulos P, Christoph DC, Griesinger F, Passlick B, Eberhardt WEE, CRISP Registry Group.   +18 more
europepmc   +1 more source

Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany. [PDF]

Ther Adv Med Oncol
Evers G, Glanemann F, Webendörfer M, Wiesweg M, Görlich D, Christoph DC, Hoffknecht P, Zimmermann H, Acker F, Sebastian M, Kerkhoff A, Mohr M, Lenz G, Hund AC, Overbeck TR, Frost N, Faehling M, Brückl WM, Kropf-Sanchen C, Schütte W, Griesinger F, Reitnauer LE, Bleckmann A.   +22 more
europepmc   +1 more source

Effects of combining durvalumab with chemotherapy in individuals suffering from advanced biliary tract cancer: an investigation into the prognostic nutritional index, systemic immune-inflammation index and patient survival outcomes. [PDF]

Am J Transl Res
Zhang X, Jin S, Han J, Zhao X.
europepmc   +1 more source

Update 2026: Management of Small Cell Lung Cancer. [PDF]

Lung
Lalla M, Dhillon P, Polat BE, Cheng H.
europepmc   +1 more source

Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population. [PDF]

Clin Transl Radiat Oncol
Peters AL, Stubbs HD, Duncan SF, Shaw A, Moore K, McGarry E, Tsim S, Lumsden G, Stares M, Phillips I, Lewis DY, Blyth KG, Maclay JD.   +12 more
europepmc   +1 more source

A 79-Year-Old Woman With Stage IIIB Lung Squamous Cell Carcinoma Presenting With Late-Onset Durvalumab‑Associated Myocarditis Requiring Differentiation From Pericardial Invasion. [PDF]

Am J Case Rep
Kodaka N, Hayashi F, Yokouchi Y, Yoshida M, Matsuse H.   +4 more
europepmc   +1 more source

Comment on Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial. [PDF]

J Gastroenterol Hepatol
Jeswani H, Jeswani AK.
europepmc   +1 more source

Erythema multiforme-like drug eruption in a patient with mycosis fungoides on durvalumab and lenalidomide. [PDF]

JAAD Case Rep
Crisan LL, Quach J, Zain J, Rosen ST, Querfeld C.   +4 more
europepmc   +1 more source

The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach. [PDF]

J Clin Med
Barretina-Ginesta MP, Lorente CM, Maximiano C, Díez R, Ec-McDa Group, Ariznavarreta A, Calvo A, Soler F.   +7 more
europepmc   +1 more source

The Dyspnea Dilemma: Immune Checkpoint Inhibitor-Associated Myocarditis Mimicking Overlapping Cardiac Pathologies-A Case Report. [PDF]

Case Rep Cardiol
Javed N, Itare V, Ashraf S, Allu SVV, Jadhav P.   +4 more
europepmc   +1 more source